Treatment Outcomes of Suprachoroidal Triamcinolone Injection in Refractory Diabetic Macular Edema
Purpose: To find out the outcomes of suprachoroidal Triamcinolone injection in refractory diabetic macular edema.
Study Design: Quasi experimental study.
Place and Duration of Study: Al-Ehsan Eye Hospital, Lahore from Jan 2020 to 31st Dec 2020.
Methods: Sixty-five patients with refractory diabetic macular edema were included. Patients underwent complete ocular history and examination. To document baseline macular edema, SD-OCT was done. The recruited patients received 0.1ml of suprachoroidal Triamcinolone injection (40mg/ml) using a 30 gauge syringe. Follow up was performed at one week, one month and third month after injection. At each follow up, best corrected visual acuity, central macular thickness and retinal nerve fiber thickness were documented. Data was analysed using SPSS version 36.0. Comparison of BCVA, central macular thickness and retinal nerve fibre layer thickness (RNFL) before and after injection was analyzed by paired sample t-test with p value of ≤ 0.05 as significant.
Results: Out of 65 patients, 29 (44.62%) were females. Mean age of patients was 54 ± 8.4 years (range 40 to 80 years). Central macular thickness after suprachoroidal Triamcinolone injection changed from 556.2 ± 10.9 to 313.6 ± 7.2 ųm. Change in visual acuity was 0.9 ± 0.01 to 0.6 ± 0.02. Pre-treatment and post-treatment visual acuities demonstrated a substantial change after undergoing treatment along with decrease in central macular thickness with p value ˂ 0.001.
Conclusion: Suprachoroidal Triamcinolone injection results in anatomical as well as functional improvement in diabetic patients with refractory macular edema.
How to Cite
Copyright (c) 2022 Muhammad Ali Haider, Nida Usman, Hasnain Muhammad Buksh, Aamna Jabran
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.